Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM

David Killock
DOI: https://doi.org/10.1038/s41571-024-00918-7
IF: 78.8
2024-06-19
Nature Reviews Clinical Oncology
Abstract:Quadruplet regimens comprising an anti-CD38 antibody, proteasome inhibitor, immunomodulatory agent and a glucocorticoid have become the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). A quadruplet regimen has also been approved for transplant-ineligible patients, although one built on a triplet containing melphalan instead of an immunomodulatory agent. Now, data from the phase III IMROZ and BENEFIT trials indicate that integration of the anti-CD38 antibody isatuximab (Isa) with the standard, first-line bortezomib (V), lenalidomide (R) and dexamethasone (d) triplet results in more durable responses in this population. In IMROZ, 446 transplant-eligible patients ≤80 years of age with NDMM were randomly assigned (3:2) to receive 4 cycles of Isa-VRd or VRd followed by continuous Isa-Rd or Rd, respectively. The primary end point was progression-free survival (PFS). At a median follow-up of 59.7 months, 60-month PFS was 63.2% with Isa-VRd versus 45.2% with VRd (HR 0.60, 98.5% CI 0.41–0.88; P < 0.001). Significantly more patients receiving Isa-VRd had a complete response or better (74.7% versus 64.1%; P = 0.01) and were rendered minimal residual disease (MRD)-negative at 10 −5 sensitivity on next-generation sequencing (55.5% versus 40.9%; P = 0.003). Although the data remain immature, a trend towards improved overall survival was also observed (72.3% versus 66.3%; HR 0.78, 99.97% CI 0.41–1.48). The two regimens were associated with similar safety profiles, rates of discontinuation owing to adverse events and quality-of-life scores, albeit with a notably higher incidence of grade ≥3 neutropenia, leukopenia and infections, second primary cancers, and fatal adverse events (mostly infections) in patients receiving Isa-VRd.
oncology
What problem does this paper attempt to address?